Service
Drug Discovery
Advanced sequencing and bioinformatics to identify novel targets and guide compound design
Key advantages
Multi-omics approach integrating genomics, transcriptomics, and proteomics
Target identification and validation through functional genomic data
Biomarker discovery for drug response, efficacy, and resistance
High-resolution tumor profiling for precision oncology drug development
Support for CRISPR and RNAi screening in early discovery phases
Customized panels and pipelines for specific therapeutic areas
Fast turnaround times with scalable sequencing workflows
Secure and collaborative data portals for research teams and partners
Technical specifications
Sample types: Tumor tissue, cell lines, organoids, blood, biofluids
Sequencing platforms: Illumina NovaSeq, PacBio, Oxford Nanopore
Data types supported: Whole genome, whole exome, RNA-Seq, single-cell RNA-Seq
Target identification methods: Differential expression, mutational hotspots, fusion detection
Output files: FASTQ, BAM, VCF, expression matrices, annotated gene lists
Bioinformatics tools: Pathway enrichment, protein interaction networks